342 related articles for article (PubMed ID: 31642878)
1. Factors Associated With Complete Remission After Rituximab Therapy for Pemphigus.
Kushner CJ; Wang S; Tovanabutra N; Tsai DE; Werth VP; Payne AS
JAMA Dermatol; 2019 Dec; 155(12):1404-1409. PubMed ID: 31642878
[TBL] [Abstract][Full Text] [Related]
2. Durable remission of pemphigus with a fixed-dose rituximab protocol.
Heelan K; Al-Mohammedi F; Smith MJ; Knowles S; Lansang P; Walsh S; Shear NH
JAMA Dermatol; 2014 Jul; 150(7):703-8. PubMed ID: 24500264
[TBL] [Abstract][Full Text] [Related]
3. Evaluation of clinical factors and outcome of systemic glucocorticoid therapy discontinuation in patients with pemphigus achieving complete remission.
Wang M; Li J; Shang P; Chong S; Chen Y; Zhao L; Wang R; Fan B; Li F; Chen X; Zhang Y; Zhao J; Dang J; Chen X; Zhu X
J Dermatol; 2023 Oct; 50(10):1347-1352. PubMed ID: 37248863
[TBL] [Abstract][Full Text] [Related]
4. Rituximab - Progress but Still Not a Final Resolution for Pemphigus Patients: Clinical Report From a Single Center Study.
Miše J; Jukić IL; Marinović B
Front Immunol; 2022; 13():884931. PubMed ID: 35592312
[TBL] [Abstract][Full Text] [Related]
5. Factors Associated With Short-term Relapse in Patients With Pemphigus Who Receive Rituximab as First-line Therapy: A Post Hoc Analysis of a Randomized Clinical Trial.
Mignard C; Maho-Vaillant M; Golinski ML; Balayé P; Prost-Squarcioni C; Houivet E; Calbo SB; Labeille B; Picard-Dahan C; Konstantinou MP; Chaby G; Richard MA; Bouaziz JD; Duvert-Lehembre S; Delaporte E; Bernard P; Caux F; Alexandre M; Ingen-Housz-Oro S; Vabres P; Quereux G; Dupuy A; Debarbieux S; Avenel-Audran M; D'Incan M; Bédane C; Bénéton N; Jullien D; Dupin N; Misery L; Machet L; Beylot-Barry M; Dereure O; Sassolas B; Benichou J; Joly P; Hébert V;
JAMA Dermatol; 2020 May; 156(5):545-552. PubMed ID: 32186656
[TBL] [Abstract][Full Text] [Related]
6. Effectiveness and safety analysis of rituximab in 146 Indian pemphigus patients: A retrospective single-center review of up to 68 months follow-up.
De D; Bishnoi A; Handa S; Mahapatra T; Mahajan R
Indian J Dermatol Venereol Leprol; 2020; 86(1):39-44. PubMed ID: 31089006
[TBL] [Abstract][Full Text] [Related]
7. Adjuvant rituximab treatment for pemphigus: A retrospective study of 45 patients at a single center with long-term follow up.
Kim TH; Choi Y; Lee SE; Lim JM; Kim SC
J Dermatol; 2017 Jun; 44(6):615-620. PubMed ID: 28186358
[TBL] [Abstract][Full Text] [Related]
8. Clinical experiences of different dosing schedules of rituximab in pemphigus with various disease severities.
Cho HH; Jin SP; Chung JH
J Eur Acad Dermatol Venereol; 2014 Feb; 28(2):186-91. PubMed ID: 23356542
[TBL] [Abstract][Full Text] [Related]
9. Efficacy of rituximab for pemphigus: a systematic review and meta-analysis of different regimens.
Wang HH; Liu CW; Li YC; Huang YC
Acta Derm Venereol; 2015 Nov; 95(8):928-32. PubMed ID: 25881672
[TBL] [Abstract][Full Text] [Related]
10. Therapy with rituximab for autoimmune pemphigus: results from a single-center observational study on 42 cases with long-term follow-up.
Cianchini G; Lupi F; Masini C; Corona R; Puddu P; De Pità O
J Am Acad Dermatol; 2012 Oct; 67(4):617-22. PubMed ID: 22243765
[TBL] [Abstract][Full Text] [Related]
11. Low-dose rituximab is effective in pemphigus.
Horváth B; Huizinga J; Pas HH; Mulder AB; Jonkman MF
Br J Dermatol; 2012 Feb; 166(2):405-12. PubMed ID: 21967609
[TBL] [Abstract][Full Text] [Related]
12. A systematic review on efficacy, safety, and treatment-durability of low-dose rituximab for the treatment of Pemphigus: special focus on COVID-19 pandemic concerns.
Tavakolpour S; Aryanian Z; Seirafianpour F; Dodangeh M; Etesami I; Daneshpazhooh M; Balighi K; Mahmoudi H; Goodarzi A
Immunopharmacol Immunotoxicol; 2021 Oct; 43(5):507-518. PubMed ID: 34287098
[TBL] [Abstract][Full Text] [Related]
13. Retrospective analysis of a single-center clinical experience toward development of curative treatment of 123 pemphigus patients with a long-term follow-up: efficacy and safety of the multidrug protocol combining intravenous immunoglobulin with the cytotoxic immunosuppressor and mitochondrion-protecting drugs.
Grando SA
Int J Dermatol; 2019 Jan; 58(1):114-125. PubMed ID: 30047585
[TBL] [Abstract][Full Text] [Related]
14. Comparing the short-term therapeutic effects and safety profiles of rituximab therapy in pemphigus vulgaris patients either early treated or later than six months.
Balighi K; Daneshpazhooh M; Akbari Z; Tavakolpour S; Azimi P; Azizpour A
J Dermatolog Treat; 2019 Jun; 30(4):346-349. PubMed ID: 30081690
[No Abstract] [Full Text] [Related]
15. A single cycle of rituximab for the treatment of severe pemphigus.
Joly P; Mouquet H; Roujeau JC; D'Incan M; Gilbert D; Jacquot S; Gougeon ML; Bedane C; Muller R; Dreno B; Doutre MS; Delaporte E; Pauwels C; Franck N; Caux F; Picard C; Tancrede-Bohin E; Bernard P; Tron F; Hertl M; Musette P
N Engl J Med; 2007 Aug; 357(6):545-52. PubMed ID: 17687130
[TBL] [Abstract][Full Text] [Related]
16. Long-term outcomes of rituximab therapy in pemphigus.
Shimanovich I; Baumann T; Schmidt E; Zillikens D; Hammers CM
J Eur Acad Dermatol Venereol; 2020 Dec; 34(12):2884-2889. PubMed ID: 32367562
[TBL] [Abstract][Full Text] [Related]
17. Clinical efficacy of rituximab in the treatment of pemphigus: A retrospective study.
Sharma VK; Bhari N; Gupta S; Sahni K; Khanna N; Ramam M; Sethuraman G
Indian J Dermatol Venereol Leprol; 2016; 82(4):389-94. PubMed ID: 27279296
[TBL] [Abstract][Full Text] [Related]
18. Comparison of the efficacy and cost-effectiveness of an immunologically targeted low-dose rituximab protocol with the conventional rheumatoid arthritis protocol in severe pemphigus.
Singh N; Handa S; Mahajan R; Sachdeva N; De D
Clin Exp Dermatol; 2022 Aug; 47(8):1508-1516. PubMed ID: 35384021
[TBL] [Abstract][Full Text] [Related]
19. Rituximab therapy in pemphigus: A long-term follow-up.
Loi C; Magnano M; Ravaioli GM; Sacchelli L; Patrizi A; Bardazzi F
Dermatol Ther; 2019 Jan; 32(1):e12763. PubMed ID: 30288877
[No Abstract] [Full Text] [Related]
20. Early rituximab treatment is associated with increased and sustained remission in pemphigus patients: A retrospective cohort of 99 patients.
Nosrati A; Mimouni T; Hodak E; Gdalevich M; Oren-Shabtai M; Levi A; Mimouni D; Leshem YA
Dermatol Ther; 2022 May; 35(5):e15397. PubMed ID: 35194896
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
